The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...

Indian River County recorded the highest rate of new cases on the Treasure Coast, with 14 per 100,000 people diagnosed with ...

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Merck on Wednesday said the Phase 3 study of the once-daily, two-drug single-tablet regimen met the success criterion for its primary efficacy hypothesis, showing non-inferiority to the three-drug ...

As Uganda prepares to commemorate World AIDS Day 2025, the Uganda AIDS Commission (UAC) has called for renewed commitment, deeper community engagement, and accelerated action to end AIDS as a public ...

Background “Prevention is better than cure,” they say. But what happens when prevention is no longer enough, when we have crossed that line and are confronted with the painful reality of a disease ...

Renovaro Inc. lost its initial bid to roll back part of its deal for a bogus HIV cure peddled by a Turkish conman later convicted of killing a blackmailer to keep the fraudulent transaction on track.

Today’s Liver Meeting presentation expands upon previous data among people living with HIV and MASLD finding that semaglutide improved weight, intra-hepatic triglyceride content, insulin resistance, ...

A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...

Long-term, low doses of THC mitigate many harmful side effects and inflammation caused by HIV and antiretroviral therapy (ART ...

In an article published in The Lancet HIV, authors including Distinguished Professor Denis Nash and Professor Constantin Yiannoutsos aim to provide the most comprehensive estimates of pediatric ...

Minimally invasive kidney cancer surgeries, using robotic and laparoscopic techniques, improve patient recovery and quality of life by enabling partial nephrectomies. A new drug combination for ...